Publications by authors named "Manisha Mone"

Claim this Profile
T
The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma.
Reinhard Dummer, Alexander Guminski, Ralf Gutzmer, Luc Dirix, Karl D Lewis, Manisha Mone

J Am Acad Dermatol· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial.
Michael R Migden, Alexander Guminski, Ralf Gutzmer, Luc Dirix, Karl D Lewis, Manisha Mone

Lancet Oncol· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study.
Michele Baccarani, Brian J Druker, Susan Branford, Dong-Wook Kim, Fabrizio Pane, Manisha Mone

Int J Hematol· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Application of melt granulation technology using twin-screw extruder in development of high-dose modified-release tablet formulation.
Madhav Vasanthavada, Yanfeng Wang, Thomas Haefele, Jay P Lakshman, Manisha Mone

J Pharm Sci· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS).
Timothy P Hughes, Andreas Hochhaus, Susan Branford, Martin C Müller, Jaspal S Kaeda, Manisha Mone

Blood· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sustained durability of responses and improved progression-free and overall survival with imatinib treatment for accelerated phase and blast crisis chronic myeloid leukemia: long-term follow-up of the STI571 0102 and 0109 trials.
Richard T Silver, Jorge Cortes, Roger Waltzman, Manisha Mone, Hagop Kantarjian

Haematologica· May 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase.
Hagop M Kantarjian, Richard A Larson, Francois Guilhot, Stephen G O'Brien, Manisha Mone

Cancer· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment.
Andreas Hochhaus, Brian Druker, Charles Sawyers, Francois Guilhot, Charles A Schiffer, Manisha Mone

Blood· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Divergent pathways of gene expression are activated by the RAGE ligands S100b and AGE-BSA.
Jessica V Valencia, Manisha Mone, Jin Zhang, Marla Weetall, Frank P Buxton

Diabetes· March 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
1
1-[2-[(5-Cyanopyridin-2-yl)amino]ethylamino]acetyl-2-(S)-pyrrolidinecarbonitrile: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties.
Edwin B Villhauer, John A Brinkman, Goli B Naderi, Beth E Dunning, Bonnie L Mangold, Manisha D Mone

J Med Chem· June 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis